Thread: GenVec Inc. - GNVC

Picked up as little today on the ACC/DIS on the charts of the last 3 days, Screwy trading but accumulation going on, CLosed at .7869 and trading at .81 AH nothing but buys!!! bid .80 ask .81... All at .81

GenVec Receives National Cancer Institute Grant to Expand Cancer Program

* Press Release
* Source: GenVec, Inc.
* On Wednesday September 30, 2009, 7:43 am EDT

o
Buzz up! 0
o Print

*
Companies:
o GenVec Inc.

GAITHERSBURG, Md., Sept. 30 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC - News) announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support the research of a new approach to treating metastatic cancer. Under this grant, valued at over $300,000, GenVec will investigate the hypothesis that the delivery of a specific gene will stimulate an antitumor response that could control cancer metastases.
Related Quotes
Symbol Price Change
GNVC 0.80 +0.06
Chart for GenVec, Inc.
{"s" : "gnvc","k" : "c10,l10,p20,t10","o" : "","j" : ""}

(Logo: http://www.newscom.com/cgi-bin/prnh/...05/DC50112LOGO )

"Funding from this grant provides GenVec with an opportunity to expand our cancer program and explore a novel approach to cancer treatment," said Dr. Douglas Brough, GenVec's Executive Director, Head of Research. "The work expected to be conducted under this grant will explore new ways to control metastases, addressing a severely unmet medical need."

About GenVec

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at Welcome To GenVec.com! :: GenVec, Inc. and in the company's various filings with the Securities and Exchange Commission.

Investor Contact: Media Contact:
GenVec, Inc. Tiberend Strategic Advisors, Inc.
Danielle M. DiPirro Andrew Mielach
(301) 944-1877 (212) 827-0020
ddipirro@genvec.com amielach@tiberendstrategicadvisors.com

The partnership with Novartis will push this stock past 10! Get in now!